| 2014 | A prospective phase II trial of s-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features | ONCOLOGY REPORTS |
| 2009 | Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| MOLECULAR CANCER THERAPEUTICS |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
| 2016 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | LUNG CANCER |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | ANNALS OF ONCOLOGY |
| 2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2017 | Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
| ONCOTARGET |
| 2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| ONCOTARGET |
| 2012 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
| CANCER |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2012 | EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI
| YONSEI MEDICAL JOURNAL |
| 2012 | Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer
| YONSEI MEDICAL JOURNAL |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | LUNG CANCER |
| 2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
| ONCOTARGET |
| 2010 | Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
| CANCER |
| 2019 | High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma
| SCIENTIFIC REPORTS |
| 2009 | High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
| CLINICAL CANCER RESEARCH |
| 2019 | Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer | Annals of Oncology |
| 2014 | Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
| GENOME MEDICINE |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | LUNG CANCER |
| 2010 | Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
| 2019 | Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer | CLINICAL LUNG CANCER |
| 2019 | Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
| PLOS ONE |
| 2017 | Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
| CANCER RESEARCH AND TREATMENT |
| 2013 | Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
| YONSEI MEDICAL JOURNAL |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2016 | PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
| ONCOTARGET |
| 2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | LUNG CANCER |
| 2009 | Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. | LUNG CANCER |
| 2005 | Primary idiopathic chylopericardium associated with cervicomediastinal cystic hygroma
| YONSEI MEDICAL JOURNAL |
| 2011 | Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
| EXPERIMENTAL AND THERAPEUTIC MEDICINE |
| 2014 | Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
| PLOS ONE |
| 2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
| 2015 | The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer | LUNG CANCER |
| 2013 | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2013 | The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
| YONSEI MEDICAL JOURNAL |
| 2008 | The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. | LUNG CANCER |
| 2011 | Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. | ANNALS OF THORACIC SURGERY |
| 2019 | Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2009 | 비소세포성 폐암으로 수술 후 방사선치료가 시행된 N2병기 환자들에서 다발 부위 종격동 림프절 전이 여부에 따른 N2병기 구분의 임상적 의미
| Journal of the Korean Society for Therapeutic Radiology and Oncology |
